Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance

Abstract

BackgroundAugmented renal clearance (ARC) refers to enhanced renal elimination of circulating solute has attracted attention widely and in recent years increasing attention has been paid to patients with ARC. A population pharmacokinetic (PPK) analysis was performed to provide a reference for clinical individual therapy of vancomycin in in ARC patients. MethodsPatients hospitalized in the First Affiliated Hospital of China Medical University from July 2013 to December 2015 and suspected or confirmed infection caused by gram-positive bacteria were enrolled in this study. The serum concentrations were determined by enzyme multiplied immunoassay technique. A nonlinear mixed effects model (NONMEM) was used to evaluate the influence of covariates on vancomycin pharmacokinetics and obtain the PPK model. Bootstrap, visual predictive checks and normalized prediction distribution errors were used to evaluate the estabolishe model. ResultsA total of 186 vancomycin serum samples from 95 patients, including 24 females and 71 males were studied. The final model was as follows:Cli=8.515×1−0.01175×Age−45×eηi and Vi=155.4×eηi. The final PPK model in ARC patients was proved to be robust and reliable. Age was identified as the most significant covariate in the final model. ConclusionsIn this study, a simple population pharmacokinetic (PPK) model of vancomycin in Chinese patients with ARC was established using a nonlinear mixed-effects model (NONMEM). The final PPK model could achieve a good predictive effect, which provides a reference for clinical individual therapy.